A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.
With temperatures rising in Middle Tennessee, doctors at Monroe Carell Jr. Children’s Hospital at Vanderbilt stress the danger of leaving children unattended in vehicles.
A drug in use clinically to help make vaccines more effective may be a powerful new tool for fighting antibiotic-resistant infections.
After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverly Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.
Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis.
Vanderbilt scientists have discovered that a certain enzyme plays a crucial role in preventing obesity-related cardiac dysfunction.